Phase 2: Measurable disease meeting the following criteria:
Adequate hepatic function within 28 days prior to study registration defined as meeting all of the following criteria:
Adequate hematologic function within 28 days prior to study registration defined as meeting all of the following criteria:
Have adequate hematologic function within 15 days prior to study treatment, defined as meeting all of the following criteria:
Unilateral or bilateral disease meeting study criteria
Donor meeting 1 of the following criteria:
Any patient not meeting the eligibility criteria
The presence of measurable disease meeting the following criteria:
Meeting the protocol definition of TNmCRC assessed in the screening blood test.
Multiple myeloma meeting the following criteria:
Active disease meeting at least 1 of the following IWCLL 2008 criteria for requiring treatment:
Disease-related: meeting one of the following diagnosis
Adequate hematologic and renal function, based upon meeting protocol defined laboratory criteria within 7 days before randomization.
Active disease meeting ? 1 of the following IWCLL 2008 criteria for requiring treatment
Active disease meeting ? 1 of the following IWCLL 2008 criteria for requiring treatment.
Measurable disease based on investigator's assessments meeting the following criteria:
Must have documented progressive disease by meeting at least one of the Prostate Cancer Working Group 2 Criteria
Positive serology for HTLV 1 or 2. Furthermore and prior to lymphodepleting chemotherapy, a subject meeting the following criteria is not eligible for participation in the study:
Patients must have progressive mCRPC defined by meeting at least one of the following criteria:
Subject is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:
Adequate hepatic function within 28 days prior to registration for protocol therapy defined as meeting all of the following criteria:
Adequate hematologic function within 28 days prior to registration for protocol therapy defined as meeting all of the following criteria:
Subjects have active disease meeting the IWCLL 2008 published criteria.
Presence of measurable disease meeting the following criteria:
Have adequate hematologic function, defined as meeting all of the following criteria:
Has, at screening, serologic laboratory tests meeting one or more of the following criteria:
Has, at screening, safety laboratory tests meeting one or more of the following criteria:
mTNBC (confirmed from most recent tissue sample) meeting the following criteria:
Presence of measurable disease meeting the following criteria:
Cardiac or peripheral vascular disease meeting any of the following criteria:
Patient must have an advanced stage malignancy defined as meeting at least one of the following criteria:
Measurable multiple myeloma disease, defined as meeting at least one of the following criteria within 14 days prior to first dose of study drug:
Laboratory values meeting the following criteria:
Presence of measurable disease meeting the following criteria:
Radiologically measurable disease meeting the following criteria:
Completed primary treatment (surgery, chemotherapy, and/or radiation) at minimum 6-8 weeks before the first group meeting, and maximum 24 months before the first group meeting, which approximates the ‘re-entry’ phase of cancer survivorship.
Multiple myeloma meeting the following criteria:
Participants who were eligible for the main trial with the exception of not meeting BMI criteria for obesity
Measurable disease meeting the following criteria and confirmed by central radiographic review:
